Of the 14 million new cancers diagnosed worldwide every year, 50–60% is characterised by at least one somatic variant of p53.13 In the HNSCC cohort from TCGA included in this study, 69.9% of patients expressed a mutation in TP53. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.